Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 8/2019

01-08-2019 | Lung Cancer | Original Article

Re-irradiation in locally recurrent lung cancer patients

Authors: Ingmar Schlampp, Juliane Rieber, Sebastian Adeberg, Farastuk Bozorgmehr, Claus Peter Heußel, Martin Steins, Jutta Kappes, Hans Hoffmann, Thomas Welzel, Jürgen Debus, Stefan Rieken

Published in: Strahlentherapie und Onkologie | Issue 8/2019

Login to get access

Abstract

Purpose

Lung cancer remains one of the tumour diagnoses with high lethality, although innovative treatment approaches have yielded improvements in local control and survival rates. There is still no consensus on how to treat local relapse in patients after first-line treatments. Radiotherapy may be considered in this situation; however, data supporting its effectiveness are rare. The purpose of this retrospective analysis was to evaluate outcomes of patients re-irradiated for thoracic tumours in terms of overall survival (OS), local progression-free survival (LPFS), toxicity and dose–volume parameters.

Patients and methods

Sixty-two patients with locally recurrent previously irradiated lung cancer were analysed retrospectively (NSCLC n = 52, SCLC n = 10). Target volumes both in lung and mediastinum were re-irradiated with conventional three-dimensional or intensity-modulated radiotherapy techniques. Median overall dose of re-irradiation was 38.5 Gy (range 20–60 Gy) with a median single dose per fraction of 2 Gy (1.8–3.0 Gy). Clinical documents and treatment plans were evaluated.

Results

Median follow-up was 8.2 months (range 0–27 months). OS following re-irradiation was 9.3 months (range: 0–27 months) and LPFS was 6.5 months (range: 0–24 months). OS and LPFS were not affected by histology, total dose or patient age and gender. OS was improved in patients whose re-irradiation volumes included less than two mediastinal lymph node stations (p = 0.016). Twelve patients suffered from pneumonitis ≥grade II (19%) and two from pneumonitis grade III. One patient presumably died from pneumonitis grade V. A slight decline in forced expiratory volume (FEV1) was detected in post-re-irradiation lung function testing.

Conclusions

Re-irradiation is an option for patients with tumour recurrence to control local progression and lower the symptom burden. Oncological outcome appears to be affected by size, location of mediastinal target volumes and lung function. Prospective clinical trials are warranted to substantiate the role of re-irradiation in recurrent lung cancer.
Literature
1.
Malvezzi M, Carioli G, Bertuccio P et al (2016) European cancer mortality predictions for the year 2016 with focus on leukaemias. Ann Oncol 27:725–731CrossRefPubMed
2.
Rodrigues G, Choy H, Bradley J et al (2015) Definitive radiation therapy in locally advanced non-small cell lung cancer: executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline. Pract Radiat Oncol 5:141–148CrossRefPubMed
3.
Bezjak A, Temin S, Franklin G et al (2015) Definitive and adjuvant radiotherapy in locally advanced non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. J Clin Oncol 33:2100–2105CrossRefPubMed
4.
Rudin CM, Ismaila N, Hann CL et al (2015) Treatment of small-cell lung cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. J Clin Oncol 33:4106–4111CrossRefPubMed
5.
Curran WJ, Paulus R, Langer CJ et al (2011) Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 103:1452–1460CrossRefPubMedPubMedCentral
6.
Turrisi AT, Kim K, Blum R et al (1999) Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265–271CrossRefPubMed
7.
Scagliotti GV, Parikh P, Von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543–3551CrossRefPubMed
8.
De Ruysscher D, Faivre-finn C, Le pechoux C et al (2014) High-dose re-irradiation following radical radiotherapy for non-small-cell lung cancer. Lancet Oncol 15:e620–e624CrossRefPubMed
9.
Mountain CF, Dresler CM (1997) Regional lymph node classification for lung cancer staging. Chest 111:1718–1723CrossRefPubMed
10.
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed
11.
12.
Bradley JD, Paulus R, Komaki R et al (2015) Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 16:187–199CrossRefPubMedPubMedCentral
13.
14.
Drodge CS, Ghosh S, Fairchild A (2014) Thoracic reirradiation for lung cancer: a literature review and practical guide. Ann Palliat Med 3:75–91PubMed
15.
Jeremić B, Videtic GM (2011) Chest reirradiation with external beam radiotherapy for locally recurrent non-small-cell lung cancer: a review. Int J Radiat Oncol Biol Phys 80:969–977CrossRefPubMed
16.
Tada T, Fukuda H, Matsui K et al (2005) Non-small-cell lung cancer: reirradiation for loco-regional relapse previously treated with radiation therapy. Int J Clin Oncol 10:247–250CrossRefPubMed
17.
Cetingoz R, Arican-alicikus Z, Nur-demiral A et al (2009) Is re-irradiation effective in symptomatic local recurrence of non small cell lung cancer patients? A single institution experience and review of the literature. J Buon 14:33–40PubMed
18.
Kruser TJ, Mccabe BP, Mehta MP et al (2014) Reirradiation for locoregionally recurrent lung cancer: outcomes in small cell and non-small cell lung carcinoma. Am J Clin Oncol 37:70–76CrossRefPubMedPubMedCentral
19.
Darby SC, Ewertz M, Mcgale P et al (2013) Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368:987–998CrossRefPubMed
20.
Ming X, Feng Y, Liu H et al (2015) Cardiac exposure in the dynamic conformal arc therapy, intensity-modulated radiotherapy and volumetric modulated arc therapy of lung cancer. PLoS ONE 10:e144211CrossRefPubMedPubMedCentral
21.
Griffioen GH, Dahele M, De haan PF, al at (2014) High-dose, conventionally fractionated thoracic reirradiation for lung tumors. Lung Cancer 83:356–362CrossRefPubMed
22.
Green N, Melbye RW (1982) Lung cancer: retreatment of local recurrence after definitive irradiation. Cancer 49:865–868CrossRefPubMed
23.
Okamoto Y, Murakami M, Yoden E et al (2002) Reirradiation for locally recurrent lung cancer previously treated with radiation therapy. Int J Radiat Oncol Biol Phys 52:390–396CrossRefPubMed
24.
Marks LB, Bentzen SM, Deasy JO et al (2010) Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys 76:70–76CrossRef
25.
26.
27.
Borst GR, De jaeger K, Belderbos JS et al (2005) Pulmonary function changes after radiotherapy in non-small-cell lung cancer patients with long-term disease-free survival. Int J Radiat Oncol Biol Phys 62:639–644CrossRefPubMed
28.
Miller KL, Zhou SM, Barrier RC et al (2003) Long-term changes in pulmonary function tests after definitive radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys 56:611–615CrossRefPubMed
Metadata
Title
Re-irradiation in locally recurrent lung cancer patients
Authors
Ingmar Schlampp
Juliane Rieber
Sebastian Adeberg
Farastuk Bozorgmehr
Claus Peter Heußel
Martin Steins
Jutta Kappes
Hans Hoffmann
Thomas Welzel
Jürgen Debus
Stefan Rieken
Publication date
01-08-2019
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 8/2019
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-019-01457-2

Other articles of this Issue 8/2019

Strahlentherapie und Onkologie 8/2019 Go to the issue

Literatur kommentiert

Wirksamkeit und Sicherheit einer Kohlenstoffionentherapie lokal rezidivierter Rektumkarzinome: Ergebnisse der J‑CROS-Studie 1404 Rektum

Original Article

Stereotactic body radiotherapy of central lung malignancies using a simultaneous integrated protection approach

Literatur kommentiert

Ganzbrust- oder Teilbrustbestrahlung nach 5 Jahren aus Patientensicht: Longitudinale Analyse der IMPORT-LOW-Phase III-Studie

Original Article

Role of perilesional edema and tumor volume in the prognosis of non-small cell lung cancer (NSCLC) undergoing radiosurgery (SRS) for brain metastases

Original Article

Adjuvant radiochemotherapy vs. chemotherapy alone in gastric cancer: a meta-analysis

Literatur kommentiert

Eine definitive Strahlentherapie mit einer Kurzzeit Androgendeprivationstherapie von 18 Monaten kann bei Patienten mit lokal begrenztem Prostatakarzinom mit hohen Risikofaktoren gegenüber dem Standard von 28–36 Monaten ausreichend sein